BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Taiwan’s Health2Sync Partners with Western Sydney Diabetes to Transform Diabetes Care Through Digital Innovation

Health2Sync, Asia’s leading digital health solutions provider, announced a new partnership with Western Sydney Diabetes . This collaboration aims to ...

December 18, 2024 | News

Eli Lilly Announces $3 Billion Expansion in Wisconsin to Boost Global Medicine Production

The investment will benefit millions of patients worldwide, boosting the production of the company's medicines, including those for diabetes and obesity&nb...

December 06, 2024 | News

OPTIMUM Tele-Monitoring System Demonstrates Significant Health Gains in Type 2 Diabetes Care in Singapore

A cutting-edge tele-monitoring system, OPTIMUM (Optimising care of Patients via Telemedicine In Monitoring and Augmenting their control of Diabetes Mellitu...

November 12, 2024 | News

Diabetes Singapore and GSK Strengthen Efforts to Tackle Rising Viral Infection Risks in Diabetes Care

Diabetes Singapore and GSK aim to enhance awareness and improve lives affected by diabetes through educational talks and activities on World Di...

November 12, 2024 | News

Hong Kong Approves Eli Lilly’s Mounjaro® as First Dual-Receptor Agonist for Obesity and Type 2 Diabetes

Adults taking Mounjaro in a clinical trial lost on average 48 lb. at the highest dose1,2 Mounjaro delivered superior A1C reductions versus all comparato...

October 28, 2024 | News

Endogenex Achieves Key Clinical Milestone with First Patient Enrolled in ReCET™ Study for Type 2 Diabetes Treatment

Achieving a Significant Clinical Milestone in Assessing the ReCET™ System as a Groundbreaking Treatment for Type 2 Diabetes Endogenex, Inc., a clini...

October 16, 2024 | News

HighTide Therapeutics Presents Promising Data on HTD1801 for Type 2 Diabetes at EASD 2024

HighTide Therapeutics, Inc. (2511.HK), a clinical-stage biopharmaceutical company dedicated to developing multifunctional therapies for chronic liver and m...

September 12, 2024 | News

Yunovia Gains MFDS Clearance for Phase 1 MAD Study of Oral GLP-1 Agonist for Diabetes and Obesity

Yunovia, a drug R&D subsidiary of Ildong Pharmaceutical Group, announced on the 26th that the Ministry of Food and Drug Safety (MFDS) of Korea has clea...

August 28, 2024 | News

FDA Expands Approval of Insulet SmartAdjust Technology to Include Type 2 Diabetes Management

U.S. Food and Drug Administration expanded the indications of the Insulet SmartAdjust technology, an interoperable automated glycemic controller previously...

August 27, 2024 | News

AiViva Biopharma Completes Enrollment in Phase 1 Trial of AIV007 for Wet AMD and DME

AiViva Biopharma Inc., a clinical-stage biotechnology company, announced that it has fully enrolled and completed dosing the last patient in a Phase 1 tria...

August 26, 2024 | News

Sanyou Bio and JiAnTeBo Forge Strategic Partnership to Innovate Metabolic Disease Therapies

Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "Sanyou Bio") and Guangdong JiAnTeBo Biotechnology Co., Ltd. (hereinafter r...

August 08, 2024 | News

MTD Expands into India and China with Ypsomed Acquisition

Medical Technology and Devices (MTD) is pleased to announce the successful closing of the acquisition of Ypsomed's Pen Needles and Blood Glucose Monitoring...

August 05, 2024 | News

Eluminex Biosciences Administers First Dose of EB-105 to Diabetic Macular Edema Patient in US

Eluminex Biosciences announced that their tri-specific fusion antibody drug, EB-105, has administered its first dose to a diabetic macular edema patient in...

July 29, 2024 | News

CordenPharma Announces €900 Million Investment to Expand Peptide Manufacturing Capabilities in US and Europe

CordenPharma has announced its largest strategic investment to date with a committed spend of ~€900m over the next 3 years to grow its Peptide technol...

July 17, 2024 | News

Stay Connected